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Background: In May 2014, Middle East respiratory syndrome coronavirus (MERS-CoV) infection, with closely related
viral genomes, was diagnosed in two Dutch residents, returning from a pilgrimage to Medina and Mecca, Kingdom
of Saudi Arabia (KSA). These patients travelled with a group of 29 other Dutch travellers. We conducted an
epidemiological assessment of the travel group to identify likely source(s) of infection and presence of potential
risk factors.
Methods: All travellers, including the two cases, completed a questionnaire focussing on potential human, animal
and food exposures to MERS-CoV. The questionnaire was modified from the WHO MERS-CoV questionnaire, taking
into account the specific route and activities of the travel group.
Results: Twelve non-cases drank unpasteurized camel milk and had contact with camels. Most travellers, including
one of the two patients (Case 1), visited local markets, where six of them consumed fruits. Two travellers, including
Case 1, were exposed to coughing patients when visiting a hospital in Medina. Four travellers, including Case 1,
visited two hospitals in Mecca. All travellers had been in contact with Case 1 while he was sick, with initially
non-respiratory complaints. The cases were found to be older than the other travellers and both had co-morbidities.
Conclusions: This epidemiological study revealed the complexity of MERS-CoV outbreak investigations with multiple
potential exposures to MERS-CoV reported such as healthcare visits, camel exposure, and exposure to untreated food
products. Exposure to MERS-CoV during a hospital visit is considered a likely source of infection for Case 1 but not for
Case 2. For Case 2, the most likely source could not be determined. Exposure to MERS-CoV via direct contact with
animals or dairy products seems unlikely for the two Dutch cases. Furthermore, exposure to a common but
still unidentified source cannot be ruled out. More comprehensive research into sources of infection in the
Arabian Peninsula is needed to strengthen and specify the prevention of MERS-CoV infections.
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In 2012, the Middle East respiratory syndrome corona-
virus (MERS-CoV) was isolated for the first time from
the sputum of a 60-year-old man who presented with an
acute pneumonia in Kingdom of Saudi Arabia (KSA) [1].
As of June 24 2014, 707 laboratory-confirmed cases of
MERS-CoV infection have been reported to the WHO
including 252 (36%) fatal cases [2]. Following the first
upsurge of cases in spring 2013, a second wave occurred
in 2014, mainly in KSA [3]. Most cases so far either re-
sided in or travelled to the Arabian Peninsula and neigh-
bouring countries or were close contacts of these cases.
Furthermore, travel related cases have been reported from
the United States of America (USA), the United Kingdom
(UK), Germany, France, Tunisia, Italy, Greece, Algeria,
Egypt, the Philippines and Malaysia [3-7].
So far, mainly sporadic cases are reported as well as a few
hospital outbreaks, which is in line with a low reproduction
rate (R0) of MERS-CoV, estimated to range from 0.4 to 1.5
[8-10]. The median incubation period is estimated to be
5.2 days (95% CI 1.9-14.7 days) [8]. For most non health-
care associated cases no clear source of infection could be
identified, although camels are considered a reservoir as
the virus and antibodies against MERS-CoV have been
identified in camels (Camelus dromedarius) and in their
milk [9,10]. The exact modes of transmission of the virus
to humans remain unclear [11-14], leaving the possibility
for other yet unidentified sources of infection. To stop or
reduce transmission of MERS-CoV and prevent new hu-
man infections, it is important to identify all potential
sources of infections as well as risk factors and route(s) of
transmission.
In May 2014, MERS-CoV infection was diagnosed in
two Dutch residents. These cases travelled with a group
of 29 other people, returning to the Netherlands from
pilgrimage to Medina and Mecca, KSA [15]. We con-
ducted a comprehensive epidemiological assessment of
the travel group aiming to identify the likely source(s) of
infection and presence of potential risk factors for these
two cases.
Methods
We compiled a questionnaire based on sample question-
naires originating from two WHO-protocols aimed to
asses risk factors and investigate contacts of patients
with MERS‐CoV infection [16,17]. We adapted the ques-
tionnaire to the specific route and activities of the Dutch
travellers. Our questionnaire covered human, animal
and food exposures to MERS-CoV during the whole trip
to KSA. The questionnaires consisted of 28 open and
closed questions, and it took approximately 20 minutes
to complete the face-to-face interview with the travellers
(Additional file 1). Nurses of the public health services
administered the questionnaires approximately 3 weeksafter return to the Netherlands. For the two cases the
questionnaire was completed with data on the travel
route and stay in KSA collected by the National Coord-
ination Centre for Communicable Disease Control.
Results
The patients were a 70-year-old man (Case 1) and his
73-year-old sister (Case 2), both having underlying car-
diovascular co-morbidities and diabetes mellitus. The
remaining travel group included 29 persons (41% male)
aged between 10 and 70 years (median age: 55 years).
Seventeen (59%) of the non-cases did not report any co-
morbidities (Table 1). Upon identification of Case 1,
throat swabs of all contacts were tested by PCR to assess
other MERS-CoV cases. Apart from Case 2, who had re-
ported mild respiratory complaints starting on the 5th of
May (t = day 9), all other 29 travellers tested negative and
did not develop symptoms.
Travel route exposures
The group made a pilgrimage to Medina and Mecca,
KSA (Figure 1). They arrived on the 26th of April 2014
(day 0) in Medina, left by private bus to Mecca on the
4th of May (day 8) and returned to Amsterdam on the
10th of May (day 14). Case 1 started to feel feverish and
had diarrhoea on the 1st of May (day 5). Respiratory
complaints started on the 10th of May (day 14). MERS-
CoV was identified in Case 1 on the 13th of May (day
17) and in Case 2 on the 14th of May (day 18). Detailed
case reports of the two patients are described by Kraaij
et al. [15]. During their pilgrimage, the whole group
stayed in the same hotels and had breakfasts together.
There was no fixed collective travel programme, but they
had some joint visits to several mosques. The travellers
also spent time alone or in smaller subgroups, visiting
different mosques, markets and restaurants.
The exposures for both the cases and 29 asymptomatic
travellers during their visit to Saudi Arabia are summa-
rized in Table 2.
Animal exposure
On the 3rd of May (day 7), 12 travellers (excluding the two
cases) made a trip to the touristic valley Wadi-e-Jinn, and
stopped when they came across a herd of camels laying
behind an improvised razor fence. Four travellers reported
direct contact with the camels. Eight travellers mentioned
indirect contact, for example via the fences surrounding
the animals. Eleven travellers consumed unpasteurized
camel milk, offered to them by the caretakers of the
camels. Besides contact with camels, two travellers re-
ported that they spotted many pigeons in the cities
and fed them. No other direct contact with animals
was mentioned.
Table 1 Self-reported co-morbidity for the 31 persons
who made a pilgrimage to Medina and Mecca, Kingdom







Cardiovascular diseases 2 (100) 4 (14)
Diabetes mellitus 2(100) 6 (21)
Other co-morbidity* 0 - 9 (31)
No com-morbidities 0 - 12 (41)
*Mainly allergy reported.
Fanoy et al. Emerging Themes in Epidemiology 2014, 11:16 Page 3 of 6
http://www.ete-online.com/content/11/1/16Food exposure
As mentioned above, eleven travellers, excluding the two
cases, consumed unpasteurized camel milk. Further-
more, 22 travellers, including Case 1, visited one or
more local markets in Medina. Seven of them, excluding
Case 1, bought and consumed a range of fruits such as
prunes and dates. Furthermore, 14 travellers bought sou-




Case 1 and his son visited two hospitals in Medina on
the 29th of April (day 3) because of eye complaints of
the son. As mentioned before, they spent 45 minutes in
a crowded waiting room of a general hospital where they
were exposed to coughing patients. Subsequently, the
son was referred to a specialized eye clinic where they
spent no time in a waiting room and did not notice any
coughing patients.Table 2 Overview of potential MERS-CoV exposures of cases a
of Saudi Arabia, April 26th - May 10th 2014
Case 1
Animal exposure
Visit to camel farm No
Direct contact with camels No
Indirect contact with camels No
Food exposures
Consumption of unpasteurized milk No
Visit to local market in Medina Yes
Consumption of fruits on market No
Buying souvenirs on market No
Human exposures
Contact with coughing patients (excluding case 1 and 2) Yes, in waiting r
Hospital visit (due to other non-MERS related illnesses) Yes
Minimal social contact with case 1 and/or 2 Case 1 and 2 ha
Daily contact with case 1 and/or 2 Case 1 and 2 ha
other and share
MERS-CoV: Middle East Respiratory Syndrome coronavirus.On the 5th of May (day 9), Case 1, accompanied by his
son, visited an emergency department of a general hospital
in Mecca because of acute malaise, weakness, nausea and
diarrhoea (without respiratory complaints). These symp-
toms started on May 1 (day 5). Case 1 and his son spend
30-45 minutes in the waiting room, though they had no
specific exposure to coughing people. On the 7th of May
(day 11) Case 1 returned to another hospital in Mecca, ac-
companied by his son, where he only briefly stayed in the
waiting room, received antibiotic treatment and was ob-
served for approximately three hours. Four other travellers,
including his son, accompanied him. Two of them did not
notice any coughing persons, while the other two did not
answer this question. Case 2 did not visit a hospital during
the pilgrimage or prior to her diagnosis in the Netherlands.
Contact with coughing persons
Two travellers (Case 1 and his son) waited 45 minutes in a
crowded waiting room of a general hospital in Medina
(29th of April, day 3) where they were exposed to cough-
ing patients. One other traveller, who did not enter a hos-
pital, reported coughing persons outdoors. The duration
and intensity of this contact was not clarified in more de-
tail. Case 1 and 2 had been in close contact with each
other during the entire trip, as they shared hotel rooms.
All 29 travellers had been in contact with both cases
during the trip. Seventeen travellers had minimal social
contact with the two cases, for example only brief eye
contact in the hotel lobby or in the bus. Twelve travel-
lers reported daily contact, such as visits to the hotel
room of Case 1 while he was sick, or accompanying him
while shopping. The son of Case 1 had the most intensivend asymptomatic travellers during a visit to the Kingdom








oom of a hospital No 2 (7%)
No 1 (3%)
d daily contact with each other 17 (59%)
d daily contact with each
d hotel rooms
12 (41%)
Figure 1 Timeline of events for two MERS-CoV patients returning to the Netherlands from Saudi Arabia, May 2014. This is a figure
created by Rita de Sousa and published in the following article in Eurosurveillance: Kraaij – Dirkzwager M, et al. [15].
Fanoy et al. Emerging Themes in Epidemiology 2014, 11:16 Page 4 of 6
http://www.ete-online.com/content/11/1/16contact sharing a hotel room with both cases. Neverthe-
less, his throat swabs tested negative to MERS-CoV by
PCR during the follow-up after the identification of Case 1.
Discussion
We found no indications that the two cases were in-
fected via contact with specific animals or dairy prod-
ucts. Infection during a hospital visit could be a source
for Case 1. Sequence analysis of parts of the viral gen-
ome collected from both patients had shown that the
strains were nearly identical, suggesting that the cases
have infected each other, or that they were exposed to a
common source. In the latter case, exposure during a
hospital visit is unlikely because Case 2 did not visit a hos-
pital before onset of disease. The possibility of asymptom-
atic infections and transmission among the accompanying
travellers cannot be ruled out, but seems unlikely in view
of the negative PCR results. Subsequently, although
considered unlikely, we cannot exclude the possibility of
asymptomatic travellers being a source of infection for
Case 1 and/or 2. No other common sources were identi-
fied although we cannot exclude the possibility of lack of
accurate recall or indirect exposure to animal excreta. It
might be possible that one or both cases were infected
during non-specific contacts with the local population
or the environment. If initial zoonotic introductions
of MERS-CoV from camels have been followed by low
level presence among the (asymptomatic) population or in
the environment at large, this might result in an ongoing
community-based outbreak, which, unlike SARS, cannot
be controlled by rigorous hospital hygiene alone.
Both patients were of older age and had comorbidities.
In general, older age and comorbidity are considered risk
factors for symptomatic MERS-CoV infections, although
this was not the case in all outbreaks [18,19]. In thisstudy, the distribution of symptoms towards higher age
and comorbidity fits this assumption. Ongoing serological
analysis upon travellers and people exposed to the case in
the Netherlands may reveal to what extent asymptomatic
infection has occurred. The remainder of the travellers did
not develop symptomatic MERS-CoV and did not have
positive PCR-test results despite exposure to camels, dairy
products and the two cases. This could point to a low
transmissibility of the virus, which is also illustrated by the
limited number of secondary infections among contacts of
import cases described elsewhere, with the reservation
that asymptomatic infections among the remaining travel-
lers cannot be excluded fully as final serologic results are
not available [5,6]. Currently, there is only limited epi-
demiological information published considering potential
sources and transmission dynamics of MERS-CoV infec-
tion within the Arabian Peninsula. Descriptive studies
among a well-defined group of travellers can therefore
provide relevant epidemiologic information, even when
the number of travellers is too small to draw definite con-
clusions. More in depth epidemiological investigation of
comparable travel groups will add to the body of evidence,
although the diversity of activities during a relatively short
trip makes accurate recall of potential exposure challen-
ging. Alternatively, prospective cohort studies among trav-
ellers to affected areas, whereby travellers are asked to
keep a daily diary, are likely to be more informative and
complete. Due to the uncertainty about the source, the de-
tailed questions of the WHO-questionnaire were a very
useful guide to decide on the most relevant exposures to
be explored, adapted to the specific route of travel.
Conclusions
The exact source of infection remains difficult to identify.
Case 1 could have been infected during his visit to a
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exposure to a common source for both Case 1 and 2 can-
not be ruled out. Besides, Case 1 may have been exposed
to a yet unidentified source and subsequently have in-
fected Case 2, or vice versa. More research to relevant
sources in the Arabian Peninsula is needed. The suggested
role of underlying disease to develop MERS-CoV infection
is in line with the age and comorbidity of the two Dutch
cases and the absence of symptomatic MERS-CoV infec-
tions among the younger and healthier travellers.
Additional file
Additional file 1: The questionnaire.
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